Heparin monitoring during cardiac surgery. Part 2: Calculating the overestimation of heparin by the activated clotting time

Perfusion

Volumn 18, Issue 5, 2003, Pages 277-281

  Raymond, Paul D ^a,b   Ray, M J ^b   Callen, S N ^b   Marsh, N A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ADULT; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CALCULATION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG MONITORING; HEART SURGERY; HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

AGED; BLOOD COAGULATION TESTS; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; DRUG MONITORING; FACTOR XA; HEPARIN; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; PHARMACOKINETICS; SURGICAL PROCEDURES, ELECTIVE; WHOLE BLOOD COAGULATION TIME;

EID: 0242720733     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659103pf673oa     Document Type: Article

References (16)

1. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685-89.
2. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003; this issue.
3. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
4. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery - a review of current and emerging techniques. Anesthesiology 1999; 91: 1122-51.
5. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69: 674-84.
6. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 85: 174-85.
7. Culliford AT, Gitel SN, Starr N et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193: 105-11.
8. Despotis GJ, Summerfield AL, Joist JH et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-82.
9. Barstad RM, Stephens RW, Hamers MJ, Sakariassen KS. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost 2000; 83: 334-37.
10. Kozek-Langenecker SA, Mohammad SF, Masaki T, Kamerath C, Cheung AK. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg 2000; 90: 808-12.
11. Lindblad B, Wakefield TW, Whitehouse WM, Stanley JC. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 1988; 22: 55-59.
12. Carr ME, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin antiplatelet effects. Thromb Res 1994; 75: 617-30.
13. Ammar T, Fisher CF. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology 1997; 86: 1382-86.
14. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781-85.
15. Shigeta O, Kojima H, Hiramatsu Y et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118: 354-60.
16. Miyashita T, Nakajima T, Hayashi Y, Kuro M. Hemostatic effects of low-dose protamine following cardiopulmonary bypass. Am J Hematol 2000; 64: 112-15.